Gilead Sciences
GILD
1,519 hedge funds and large institutions have $69.4B invested in Gilead Sciences in 2017 Q2 according to their latest regulatory filings, with 105 funds opening new positions, 590 increasing their positions, 663 reducing their positions, and 93 closing their positions.
13% more first-time investments, than exits
New positions opened: 105 | Existing positions closed: 93
1% more funds holding in top 10
Funds holding in top 10: 88 → 89 (+1)
4% more capital invested
Capital invested by funds: $66.4B → $69.4B (+$2.97B)
0.2% more ownership
Funds ownership: 74.76% → 74.96% (+0.2%)
0% less funds holding
Funds holding: 1,524 → 1,519 (-5)
11% less repeat investments, than reductions
Existing positions increased: 590 | Existing positions reduced: 663
28% less call options, than puts
Call options by funds: $1.68B | Put options by funds: $2.33B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OppenheimerFunds
New York
|
+$246M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$234M |
| 3 |
Parnassus Investments
San Francisco,
California
|
+$182M |
| 4 |
Renaissance Technologies
New York
|
+$180M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$143M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$602M |
| 2 |
Temasek Holdings
Singapore
|
-$221M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
-$211M |
| 4 |
Los Angeles Capital Management
Los Angeles,
California
|
-$161M |
| 5 |
State Street
Boston,
Massachusetts
|
-$126M |
GILD Hedge Fund Activity: Q2 2017 in Review
1,519 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q2 2017, worth a combined $69.4B — up 4.5% from $66.4B a quarter earlier.
Buyers outnumbered sellers: 105 funds opened new GILD positions and 93 closed out — a net gain of 12 holders — while 590 added to existing stakes and 663 trimmed.
The largest buyer was OppenheimerFunds, adding an estimated $246M. The largest seller was Capital World Investors, cutting an estimated $602M.
- 1,519 institutional investors held Gilead Sciences (GILD) as of Q2 2017, down from 1,524 in Q1 2017.
- Funds reported $69.4B of Gilead Sciences stock for Q2 2017, up 4.5% quarter-over-quarter.
- 105 funds opened new Gilead Sciences positions in Q2 2017 and 93 closed out, a net change of +12 holders.
- The largest Gilead Sciences buyer in Q2 2017 was OppenheimerFunds, an estimated $246M added.
- The largest Gilead Sciences seller in Q2 2017 was Capital World Investors, an estimated $602M sold.
Based on aggregated 13F filings for Q2 2017.